Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials Journal Article
| Authors: | Molina, A. M.; Lin, X.; Korytowsky, B.; Matczak, E.; Lechuga, M. J.; Wiltshire, R.; Motzer, R. J. |
| Article Title: | Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials |
| Abstract: | Background Retrospective analyses were performed in patients with metastatic renal cell carcinoma (mRCC) to characterise the objective response (OR) rate to sunitinib and differentiate pretreatment features and outcomes of patients with early (response by ≤12 weeks) versus late response, and responders versus non-responders. Methods Data were pooled from 1059 patients in six trials. Median progression-free survival (PFS) and overall survival (OS) were estimated by Brookmeyer and Crowley method and compared between groups by log-rank test. Baseline characteristics were compared by Fisher-exact, t-, or Wilcoxon rank-sum tests. Associations between characteristics and survival were investigated by Cox proportional regression analysis. Results 398 patients (38%) had confirmed OR (12 complete responses); 26%, 61%, 79% and 86% responded by 6, 12, 18 and 24 weeks, respectively. Median (range) time to tumour response (TTR) was 10.6 (2.7-94.4) weeks and was similar in treatment-naïve and cytokine-refractory patients. Median response duration in early and late responders was 52.0 and 55.0 weeks, respectively. Median PFS in early versus late responders was 13.8 versus 20.2 months (P = 0.001); however, median OS did not significantly differ (37.8 versus 40.8 months; P = 0.144). Early responders had more lung metastases (P < 0.01), but baseline characteristics were otherwise mostly similar. Median PFS (16.3 versus 5.3 months) and OS (40.1 versus 14.5 months) were longer in responders versus non-responders (both P < 0.001); responders had more favourable prognostic factors. Conclusions OR occurred in 38% of sunitinib-treated mRCC patients. Sixty-one percent of responses occurred by 12 weeks of therapy, and responders had favourable pretreatment features and significantly longer survival. © 2013 Elsevier Ltd. All rights reserved. |
| Keywords: | sunitinib; objective response; metastatic renal cell carcinoma |
| Journal Title: | European Journal of Cancer |
| Volume: | 50 |
| Issue: | 2 |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-01-01 |
| Start Page: | 351 |
| End Page: | 358 |
| Language: | English |
| DOI: | 10.1016/j.ejca.2013.08.021 |
| PROVIDER: | scopus |
| PUBMED: | 24051327 |
| DOI/URL: | |
| Notes: | Export Date: 3 February 2014 -- CODEN: EJCAE -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work